Key facts
- It has raised $190K; the latest was Accelerator/Incubator ($120K) in Jan 2026.
- Notable investors include University of California, CONNECT (San Diego), VentureWell, rpv, 757 Collab — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for ReBlood Rx
- ·The full record, as it builds
Funding rounds
No funding rounds for ReBlood Rx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ReBlood Rx
Developer of an oxygen delivery system designed to treat hemorrhagic shock in environments where blood availability is low. The company solves the persistent issue of blood shortages in both humans and animals by offering a safe, efficient, and universally compatible system for oxygen delivery in diverse medical scenarios, enabling doctors to fill critical gaps in emergency care, surgical procedures, and remote healthcare and save patients' lives.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2023
- Employees
- 4
- Website
- rebloodrx.com/
- Ownership
- Privately Held (backing)
ReBlood Rx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ReBlood Rx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ReBlood Rx in its N-PORT filings yet. We sweep new filings monthly.